本文已被：浏览 292次 下载 288次
投稿时间：2023-09-08 网络发布日期：2024-06-20
投稿时间：2023-09-08 网络发布日期：2024-06-20
中文摘要: 目的 探讨经尿道钬激光膀胱肿瘤整块切除术（HOLRBT）与经尿道膀胱肿瘤电切术（TURBT）治疗非浸润性膀胱癌的疗效与预后。方法 选取2019年1月至2021年5月于安徽医科大学第三附属医院接受诊治的非浸润性膀胱癌患者86例作为研究对象，按照随机数字表法分为观察组（予以HOLRBT治疗）与对照组（予以TURBT治疗），各43例。对比手术时间、住院时间、出血量、膀胱冲洗时间、导尿管留置时间、外周血淋巴细胞亚群（CD4+、CD8+、CD4+/CD8+）、血清微小RNA-119a (miR-119a)、细胞角蛋白片段抗原（CYFRA21-1）、尿液核基质蛋白22（NMP-22）水平以及并发症发生率、复发率及生存时间。结果 两组手术时间、住院时间、并发症发生率比较，差异无统计学意义（P＞0.05）；观察组的出血量、膀胱冲洗时间、导尿管留置时间均短于对照组（P＜0.05）。两组术前CD4+、CD8+、CD4+/CD8+、miR-119a、CYFRA21-1、NMP-22比较，差异无统计学意义（P＞0.05）；术后3 d，观察组的CD4+、CD4+/CD8+高于对照组，而CD8+、miR-119a、CYFRA21-1、NMP-22低于对照组（P＜0.05）。随访至2023年6月，观察组的术后1年、2年复发率低于对照组，无进展生存时间长于对照组（P＜0.05）。结论 HOLRBT治疗非浸润性膀胱癌具有较为理想的效果，有利于延长患者术后无进展生存时间和降低复发率。
中文关键词: 经尿道钬激光膀胱肿瘤整块切除术 经尿道膀胱肿瘤电切术 非浸润性膀胱癌 预后
Abstract:Objective To investigate the efficacy and prognosis of transurethral holmium laser en-bloc resection of bladder tumor (HOLRBT) and transurethral resection of bladder tumor (TURBT) in the treatment of non-invasive bladder cancer. Methods Eighty-six patients with non-invasive bladder cancer treated in the Third Affiliated Hospital of Anhui Medical University from January 2019 to May 2021 were selected as the study subjects. According to the random number table method, they were divided into the observation group (treated with HOLRBT) and the control group (treated with TURBT), with 43 patients in each group. The following indexes were compared, including operation time, hospital stay, bleeding volume, bladder irrigation time, urinary catheter retention time, peripheral blood lymphocyte subsets（CD4+, CD8+, CD4+/CD8+）, serum micro-RNA-119a (miR-119a), cytokeratin fragment antigen (CYFRA21-1), urine nuclear matrix protein 22 (NMP-22) levels, as well as the complications rates, recurrence rates and survival time. Results There was no statistically significant difference in operation time, hospital stay, and complication incidence between the two groups (P＞0.05). The bleeding volume, bladder irrigation time, and urinary catheter retention time in the observation group were shorter than those in the control group (P＜0.05). There was no statistically significant difference in preoperative CD4+, CD8+, CD4+/CD8+, miR-119a, CYFRA21-A and NMP-22 (P＞0.05). Three days after surgery, levels of CD4+ and CD4+/CD8+ in the observation group were higher than those in the control group, while levels of CD8+, miR-119a, CYFRA21-A, and NMP-22 were lower than those in the control group (P＜0.05). During the follow-up to June 2023, the 1-year and 2-year postoperative recurrence rates in the observation group were lower than those in the control group, while the progression-free survival time was longer than that in the control group (P＜0.05). Conclusion HOLRBT has an ideal effect in the treatment of non-invasive bladder cancer, which is conducive to prolonging the postoperative progression-free survival time and reducing the recurrence rate of patients.
keywords: Transurethral holmium laser en-bloc resection of bladder tumors Transurethral resection of bladder tumors Non-invasive bladder cancer Prognosis
文章编号： 中图分类号：R737.14 文献标志码：A
基金项目:安徽高校自然科学研究项目（KJ2021A0777）
附件
引用文本：
孙铖,张超,李清华,等.经尿道钬激光膀胱肿瘤整块切除术治疗非浸润性膀胱癌的疗效与预后[J].中国临床研究,2024,37(6):908-911,916.
孙铖,张超,李清华,等.经尿道钬激光膀胱肿瘤整块切除术治疗非浸润性膀胱癌的疗效与预后[J].中国临床研究,2024,37(6):908-911,916.